We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Synthorx

News List

Sanofi announces it will acquire Synthorx for $2.5 billion europeanpharmaceuticalreview
December 16, 2019
Sanofi has announced it is to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion.
Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline pharmaceutical-business-review
December 12, 2019
Sanofi has agreed to acquire US-based clinical-stage biotechnology company Synthorx for about $2.5bn in an all-cash deal in a move to strengthen its immuno-oncology (IO) pipeline.
Sanofi agrees to pay $2.5bn for biotech firm Synthorx pharmaceutical-technology
December 10, 2019
French pharmaceutical company Sanofi has agreed to acquire all outstanding shares of biotechnology firm Synthorx for a total consideration of $2.5bn, or $68 per share in cash.
Preclinical biotech Synthorx wants a $100M IPO fiercebiotech
November 15, 2018
Moderna will be getting all the headlines for its monster $500 million IPO attempt this week, but that shouldn’t overshadow the major $100 million IPO that early-stage Synthorx has just announced, and what this says about the biotech market.
Synthorx reels in $63M to push synthetic cytokines into the clinic pharmafile
May 02, 2018
Synthorx raised a $63 million series C that will advance its pipelines of synthetic cytokines, which are designed to improve the efficacy ...